Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients

Gautschi, Oliver; Hügli, Barbara; Ziegler, Annemarie; Bigosch, Colette; Bowers, Naomi L.; Ratschiller, Daniel; Jermann, Monika; Stahel, Rolf A.; Heighway, Jim; Betticher, Daniel

doi:10.1016/j.lungcan.2005.10.025

Cited by 34 publications

(25 citation statements)

References 38 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heterogeneity was explored using subgroup analysis (10) with ethnicity (Asians and Caucasians) and cancer types. We have classified the cancer types in nine different categories including breast (13)(14)(15)(16)(17)(18)(19), colorectal (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), gynecologic [ovarian (35), cervical (36), and endometrial (37)], digestive tract [oral (38)(39)(40), esophageal (41)(42)(43)(44), and stomach (45,46)], blood-related [acute lymphoblastic leukemia (47), mantle cell lymphoma (48), and non-Hodgkin's lymphoma (49)], genitourinary [bladder (50)(51)(52)(53), prostate (54,55), and kidney (56)], lung (57)(58)(59)…”

Section: Methodsmentioning

confidence: 99%

Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis

Pabalan

Bapat

Sung

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

The G870A polymorphism in the CCND1 gene may influence cancer risk. However, data from published studies with individual low statistical power have been controversial. To evaluate whether combined evidence shows an association between this polymorphism and cancer, we considered all available studies in a meta-analysis. Sixty studies were combined representing data for 18,411 cases and 22,209 controls. In our meta-analysis, we investigated overall sample and two ethnic populations (Caucasians and Asians) as well as nine cancer subtypes. Individuals who are homozygous for A allele (AA) were found to be associated with significantly increased cancer risk in overall sample [odds ratio (OR), 1.23; 95% confidence interval (95% CI), 1.13-1.33; P V 0.0001], Caucasians (OR, 1.16; 95% CI, 1.07-1.26; P = 0.0002), and Asians (OR, 1.26; 95% CI, 1.14-1.39; P V 0.001). Among the nine cancer subtypes investigated, modestly significant risk (ORs, 1.08 to 1.51; P = 0.02 to 0.04) was detected in breast, colorectal, head and neck, and other cancers. Highly significant and increased risk was found to be associated with genitourinary (OR, 1.51; 95% CI, 1.20-1.89; P = 0.0004) and blood-related cancers (OR, 1.62; 95% CI, 1.28-2.

show abstract

Section: Methodsmentioning

confidence: 99%

Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis

Pabalan

Bapat

Sung

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…In the literature, several studies showed that the genotypes of CNND1 A870G were associated with lung cancer risk and clinical outcome (Betticher et al, 1996;Gautschi et al, 2006). The CCND1 gene is located at 11q13 and can act as an oncogene (Hinds et al, 1994).…”

Section: Discussionmentioning

confidence: 99%

“…The CCND1 gene has a G to A polymorphism (G870A) at codon 242 in exon 4, which increases the frequency of alternative splicing, leading to an altered protein that does not contain the sequence involved in protein turnover and then has a longer half-life (Knudsen et al, 2006). To date, many epidemiological studies have been conducted to explore the relationship between the CCND1 G870A polymorphism and lung cancer risk (Qiuling et al, 2003;Gautschi et al, 2006;Hung et al, 2006;Sobti et al, 2006;Hsia et al, 2011). However, the findings were inclusive, partially due to the possible small effect of the polymorphism on lung cancer risk and the relatively small sample size in each of published studies.…”

Section: Effects Of the Cyclin D1 Polymorphism On Lung Cancer Risk -Amentioning

confidence: 99%

“…A total of 10 case-control studies with a total of 10, 548 subjects on the association between CCND1 G870A polymorphism and lung cancer risk were included for this meta-analysis (Qiuling et al, 2003;Wang et al, 2003;Buch et al, 2005;Gautschi et al, 2006;Hung et al, 2006;Sobti et al, 2006;Wang et al, 2007;Wang et al, 2008;Li et al, 2009;Hsia et al, 2011). There were four studies of European population (Buch et al, 2005;Gautschi et al, 2006;Hung et al, 2006;Wang et al, 2007), five studies of Asians (Qiuling et al, 2003;Wang et al, 2003;Wang et al, 2008;Li et al, 2009;Hsia et al, 2011) and one study of mixed population (Sobti et al, 2006).…”

Section: Eligible Studiesmentioning

confidence: 99%

“…There were four studies of European population (Buch et al, 2005;Gautschi et al, 2006;Hung et al, 2006;Wang et al, 2007), five studies of Asians (Qiuling et al, 2003;Wang et al, 2003;Wang et al, 2008;Li et al, 2009;Hsia et al, 2011) and one study of mixed population (Sobti et al, 2006). There were about 80.0% studies using the classic PCR-RFLP assay to genotype the CCND1 G870A polymorphism.…”

Section: Eligible Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Effects of the Cyclin D1 Polymorphism on Lung Cancer Risk - a Meta-analysis

Zhang²,

Geng³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients

Müller

Dally

Klappenecker

et al. 2009

Intl Journal of Cancer

View full text Add to dashboard Cite

The prognosis of lung cancer patients treated with chemotherapy is poor, motivating the search for predictive factors. Single nucleotide polymorphisms (SNPs) in membrane transporter genes could influence the pharmacokinetics of cytostatic drugs and therefore affect treatment outcome. We examined 6 SNPs with known or suspected phenotypic effect: ABCG2 G34A, C421A; ABCC3 C2211T, G3890A, C3942T and CNT1 G565A. For 349 Caucasian patients with primary lung cancer [161 small cell lung cancer (SCLC), 187 nonsmall cell lung cancer (NSCLC) and 1 mixed] receiving first-line chemotherapy 3 different endpoints were analyzed: response after the 2nd cycle (R), progression-free survival (PFS) and overall survival (OS). The prognostic value of the SNPs was analyzed using multivariable logistic regression, calculating odds ratios (ORs) when comparing genotype frequencies in responders and nonresponders after the 2nd cycle. Hazard ratios (HRs) for PFS and for OS were calculated using Cox regression methods. In all lung cancer patients, none of the investigated polymorphisms modified response statistically significant. The only significant result in the histological subpopulations was in SCLC patients carrying the ABCC3 -211T allele who showed significantly worsened PFS (HR: 1.79; 95% confidence interval (CI) 1.13-2.82).In an exploratory subgroup analysis significantly worse OS was seen for carriers of the ABCG2 421A-allele treated with platinumbased drugs (HR: 1.60; 95% CI 1.04-2.47; n 5 256). In conclusion, this study prioritizes ABCC3 C-211T and ABCG2 C421A as candidate transporter SNPs to be further investigated as possible predictors of the clinical outcome of chemotherapy in lung cancer patients. ' 2008 Wiley-Liss, Inc.Key words: lung neoplasms; multidrug resistance-associated proteins; ABCC3, ABCG2, CNT1; pharmacogenetics Despite various improvements in the treatment of lung cancer the overall prognosis remains poor: In Germany the 5-year survival rate is 12% for men and 14% for women. 1 Patients can be treated by surgery, radiation and chemotherapy alone or in combination, using standard treatment protocols. 2 Nonsmall cell lung cancer (NSCLC) patients with localized tumors are mostly treated surgically while nonlocalized NSCLC is primarily treated with radiotherapy. Small cell lung cancer (SCLC) is mostly treated by chemotherapy with or without radiotherapy. In Europe between 1980 and 1997, the fraction of patients receiving chemotherapy has increased, especially of patients at a later tumor stage. 3 Even in patients that are comparable regarding histology, tumor stage and age there is great variation in the response to chemotherapy. 4,5 In part, this is due to genetic diversity caused by single nucleotide polymorphisms (SNPs) in genes involved in the metabolism and transport of chemotherapeutic drugs. In NSCLC patients treated with irinotecan and cisplatin, the UGT1A1 genotype significantly influenced the pharmacokinetics of the drugs, progressionfree survival (PFS) and overall survival (OS). 6 Sohn et al. 7 showed that...

show abstract

Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients

Cited by 34 publications

References 38 publications

Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis

Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis

Effects of the Cyclin D1 Polymorphism on Lung Cancer Risk - a Meta-analysis

Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients

Contact Info

Product

Resources

About